Company Focus
Chiesi Farmaceutici
Latest Chiesi Farmaceutici News
Pharmaceutical
Family-controlled Italian drugmaker Chiesi Group has announced financial results for the six months ended June 30, 2025. 16 September 2025
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company developing oral therapies for bradykinin-mediated angioedema, led by deucrictibant for hereditary angioedema (HAE) as both on-demand and prophylactic treatment options.
Latest News & Features of interest to Chiesi Farmaceutici
Biotechnology
Important regulatory news last week included Otsuka gaining accelerated Food and Drug Administration approval for its Voyxact (sibeprenlimab) for immunoglobulin A nephrology, India’s Sun Pharma for its Unloxcyt and Swiss giant Novartis for its spinal muscular atrophy drug Itvisma. Also of note, the US Centers for Medicare and Medicaid reported savings achieved in a second round of price negotiations. 30 November 2025
Pharmaceutical
India’s pharmaceutical sector is witnessing global majors deepening their footprint in advanced therapies. 29 November 2025
Biotechnology
Australia’s Therapeutic Goods Administration (TGA) has issued a safety warning regarding the discontinuation of Prolia (denosumab), originated by US biotech major Amgen, and biosimilar versions of the drug. 27 November 2025
Biosimilars
Israel’s Teva Pharmaceutical Industries has announced that the European Commission (EC) has granted marketing authorizations for its two denosumab biosimilar candidates. 25 November 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of children two years and older, teens and adults living with spinal muscular atrophy (SMA) with a confirmed mutation in the survival motor neuron 1 (SMN1) gene, making it the first and only gene replacement therapy available for this broad population. 25 November 2025
Pharmaceutical
The US District Court for the District of Columbia has rejected Israel-headquartered Teva Pharmaceuticals Industries’ challenge to the Medicare Drug Price Negotiation Program - marking the 16th defeat against the industry’s nationwide legal campaign to prevent the law from lowering prices. 24 November 2025
Biosimilars
Germany’s STADA Arzneimittel has received marketing authorizations from the European Commission (EC) for its Kefdensis and Zvogra denosumab biosimilars. 24 November 2025
Pharmaceutical
Germany’s Bayer has announced positive top-line results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. 24 November 2025
Pharmaceutical
Last week Dutch firm Merus inked a deal with USA-based Halozyme for the latter’s ENHANZE technology to deliver cancer candidate petosemtamab. Arrowhead Pharmaceuticals gained US Food and Drug Administration (FDA) approval for its familial chylomicronemia syndrome (FCS) drug Redemplo (plozasiran). US drugmaker Agios Pharmaceuticals released mixed Phase III data on its sickle cell disease candidate mitapivat. US vaccine specialist Moderna last week held an investor meeting outlining its three year goals plan. 23 November 2025
Biotechnology
UK pharma major AstraZeneca has announced plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland, USA. 22 November 2025
Latest In Brief for Chiesi Farmaceutici
Generics
India’s Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) for diroximel fumarate delayed-release capsules, 231mg (Biogen’s Vumerity delayed-release capsules, 231mg). 18 November 2025
Latest Relevant Ones To Watch News
Last week saw the end of the bidding war for Metsera, with the company accepting an improved offer from Pfizer and counter bidder Novo Nordisk pulling out. Also on Friday, Merck & Co announced a $9.2 billion bid for Cidara Therapeutics. On the research front, Roche released Phase III results for its fenebrutinib in patients with relapsing multiple sclerosis. Also, Canada’s enGene Holdings revealed encouraging new data for its bladder cancer candidate detalimogene voraplasmid. Kura Oncology and partner Kyowa Kirin last week gained earlier than expected US Food and Drug Administration for their acute myeloid leukemia drug Komzifti (ziftomenib). 16 November 2025
27 October 2025
14 October 2025
8 October 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze